Explore the key hurdles to anticipating the initial and potential value of the NASH therapy market:
• See how lack of marketed analogs and uncertainty over surrogate endpoints relevance complicates NASH pricing
• Compare potential manufacturer pricing strategies
• Weigh how payers’ response to prohibitively high costs in the past will play out today
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: